Affymetrix announced their net loss.
Affymetrix is a leader company at the gene expression science.
Of course, this quarter isn't good, but their business is growing and spreading now.
Therefore, their damage would be temporal.
Surely, this news title is sensational.
We will soon understand that truth is different from what we feel from this title.
Their businesses are segmented by three now.
The clinical segment is expected to be a next back bone near future.
This is growing up by 20% compared to 2011.
Genetic expression remains Affy's most challenged business. On the conference call Witney said that the business, which constitutes about 45 percent of Affy's total revenues, is expected to decline between 5 and 10 percent in 2012.
The genetic analysis and clinical diagnostics business unit, meanwhile, is Affy's "most robust growth opportunities," and is projected to grow at least 20 percent in 2012, Witney said.
The third business unit is life science reagents, which has seen mid-single digit growth and now makes up about 12 percent of product sales.
The company is "aggressively attacking market segments where our technologies bring significant value, such as clinical validation," Witney said in a statement. "In addition, we are pleased with the progress of our clinical program, particularly our CytoScan [research-use only] cytogenetics product."
Affymetrix Q4 Revenues Drop 23 Percent; Misses Analysts' Estimates | GenomeWeb
